Cholera is a disease of poverty and spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization (WHO) estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Their current recommended prevention method is the two-dose oral cholera vaccine (OCV); vaccination campaigns, however, require extensive planning and time for efficacy, which may not be feasible for immediate protection during an outbreak in areas with poor infrastructure. The earliest onset of protection is three weeks after the administration of the first dose. Household members often present with cholera symptoms two to three days after the initial patient becomes sick. Therefore, there is currently an unmet need for a clinical intervention to stem the community spread of cholera using a rapid prophylactic treatment. PhagePro fills this gap with its first product, ProphaLytic-VC.
WHAT IS PROPHALYTIC-VC?
ProphaLytic-VC is an orally dosed preparation of bacteriophage that is specifically targeted towards epidemic strains of cholera. It is an immediate intervention that will protect household members of a cholera patient, who are at an extremely high risk of infection. Fast and effective, ProphaLytic-VC’s targeted deployment will prevent an epidemic from taking hold in a community. Since it is ingested orally in liquid form, ProphaLytic-VC is easy to administer, especially to children who are particularly susceptible to cholera infection. In addition, those exposed to cholera infections can feel safe while taking care of community members who are sick. ProphaLytic-VC will be one arm of a comprehensive strategy that includes water sanitation, hygiene behaviors, and OCVs for preventing and controlling cholera.